RxDoctor Payments Data

Lina Rodriguez Rosario, MD

Neurology · Melbourne, FLNPI 1144450164

Payments from drug & device makers

$68,662in general payments, 2019–2025

Across 489 payments — averaging $140.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$23K
  • AbbVie$17K
  • Biohaven Pharmaceutical Holding Company Ltd.$13K
  • Biohaven Pharmaceuticals, Inc.$9K
  • UCB, Inc.$770
  • Sunovion Pharmaceuticals Inc.$434
  • plus $5K from 52 others

What the payments were for

  • Consulting fees$1,0001%
  • Speaking & faculty fees$57,96484%
  • Travel & lodging$1170%
  • Food & beverage$9,49914%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.52$23,350
AbbVie(2 entities)89$17,038
Biohaven Pharmaceutical Holding Company Ltd.14$12,781
Biohaven Pharmaceuticals, Inc.15$9,070
UCB, Inc.45$770
Sunovion Pharmaceuticals Inc.22$434
SK Life Science, Inc.10$328
Avanir Pharmaceuticals, Inc.13$303
Eisai Inc.16$280
Amgen14$264
Catalyst Pharmaceuticals, Inc.10$260
AstraZeneca15$245
Acadia Pharmaceuticals Inc17$245
Neurelis, Inc.8$237
Greenwich Biosciences, Inc.9$212
Livanova USA, Inc.10$190
Biogen2$189
Supernus Pharmaceuticals, Inc.9$165
Novartis11$162
Lilly USA, LLC11$149
Lundbeck LLC6$130
Sanofi7$124
Otsuka America Pharmaceutical, Inc.2$124
Johnson & Johnson5$119
Acorda Therapeutics, Inc6$113
Genentech USA, Inc.6$98
GSK1$97
Kyowa Kirin, Inc.5$94
EMD Serono, Inc.4$92
Takeda Pharmaceuticals U.S.A., Inc.3$84
CSL Behring3$71
Neuropace, Inc.2$66
Novocure Inc.1$64
Sumitomo Pharma America, Inc.4$61
Merz North America, Inc.3$52
Grifols USA, LLC3$49
Adamas Pharmaceuticals, Inc.4$48
Neurocrine Biosciences, Inc.2$44
MDD US Operations, LLC3$40
Almatica Pharma LLC2$39
Aucta Pharmaceuticals, Inc.4$33
Mallinckrodt Hospital Products Inc.2$30
Upsher-smith Laboratories LLC2$29
Bayer2$29
Alnylam Pharmaceuticals Inc.1$28
Tanabe Pharma America, Inc.2$27
Mallinckrodt Enterprises LLC1$24
Jazz Pharmaceuticals Inc.1$23
Ultragenyx Pharmaceutical Inc.1$20
Assertio Therapeutics, Inc.1$19
Ipsen Biopharmaceuticals, Inc1$18
Bristol Myers Squibb1$18
Merz Pharmaceuticals, LLC1$15
Argenx US, Inc.1$15
ANI Pharmaceuticals, Inc.1$14
Portola Pharmaceuticals, LLC1$14
Boston Scientific1$13
Strongbridge US Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,662 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$143,837
Medicare patients
412
Services billed
3,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)17$189,334
Lamictal XrLamotrigine14$83,069
XcopriCenobamate11$66,290
NayzilamMidazolam24$65,551
BriviactBrivaracetam35$63,665
QuliptaAtogepant41$58,760
RexultiBrexpiprazole33$47,612
FycompaPerampanel17$31,728
Aimovig AutoinjectorErenumab-Aooe27$30,508
Clobazam71$28,517
AptiomEslicarbazepine Acetate12$26,220
TopamaxTopiramate12$24,405
Nurtec OdtRimegepant Sulfate18$22,908
KeppraLevetiracetam17$21,625
VimpatLacosamide11$21,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Nayzilam, Briviact, Vimpat$770$150,28770 claims
SK Life Science, Inc.Xcopri$328$66,29011 claims
AbbVieQulipta$17,038$58,76041 claims
Otsuka America Pharmaceutical, Inc.Rexulti$124$47,61233 claims
Eisai Inc.Fycompa, Dayvigo$280$35,31228 claims
Sunovion Pharmaceuticals Inc.Aptiom$434$26,22012 claims
Upsher-smith Laboratories LLCTopiramate$29$1,706126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →